

Anti-Mouse CD274/PD-L1-153Eu

Catalog: 3153016B

Package size: 100 tests

Storage: Store at 4 °C. Do not freeze.

Clone: 10F.9G2


Isotype: Rat IgG2b

Formulation: Antibody stabilizer with 0.05% sodium azide

Technical Information

Validation: Each lot of conjugated antibody is quality control-tested by CyTOF[®] analysis of stained cells using the appropriate positive and negative cell staining and/or activation controls.

Recommended usage: The suggested use is 1 µL for up to 3×10^6 live cells in 100 µL. It is recommended that the antibody be titrated for optimal performance for each of the desired applications.



Mouse splenocytes were incubated for 3 days in media alone (left) or with concanavalin A (right) and then stained with 172Yb-anti-CD4 (RM4-5) and 153Eu-anti-CD274/PD-L1 (10F.9G2). Viable CD3+CD19- cells are displayed in the analysis.

Description

PD-L1 (also known as CD274, B7-H1), one of the ligands for programmed cell death 1 (PD-1), is an immune-inhibitory receptor belonging to the CD28/cytotoxic T lymphocyte antigen 4 (CTLA-4) family. It can deliver an inhibitory signal to PD-1/B7-1-expressing T cells, resulting in immune-suppressive effects. PD-L1 is expressed on activated T cells, B cells, NK cells, DCs, macrophages, and bone marrow-derived mast cells. PD-L1 expression is also found on a wide range of human tumors. In addition, studies have shown that PD-L1 expression strongly correlates with unfavorable prognosis in kidney, ovarian, bladder, breast, liver, gastric, and pancreatic cancer, but not in non-small cell lung cancer (NSCLC). Most importantly, these studies reveal that higher expression of PD-L1 may facilitate advancement of tumor stage and increase invasion potential. PD-L1 expression can be induced by many inflammatory mediators and cytokines, of which interferon- γ (IFN- γ) is the most potent.

References

- Bandura, D.R. et al. "Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry." *Analytical Chemistry* 81 (2009): 6,813–22.
- Ornatsky, O.I. et al. "Highly multiparametric analysis by mass cytometry." *Journal of Immunological Methods* 361 (2010): 1–20.

For technical support visit <http://techsupport.fluidigm.com>. | For general support visit www.fluidigm.com/support.

For Research Use Only. Not for use in diagnostic procedures.

This product contains antibodies manufactured by and sold under license from BioLegend[®] and licensees thereof. Information in this publication is subject to change without notice. **Safety data sheet information:** www.fluidigm.com/sds. **Patent and license information:** www.fluidigm.com/legalnotices. **EU's WEEE directive information:** www.fluidigm.com/compliance. Fluidigm, the Fluidigm logo, and CyTOF are trademarks or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. © 2017 Fluidigm Corporation. All rights reserved. 08/2017